Company Profile
Kura Oncology Stock Price, News & Catalysts
- Ticker:
- KURA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
11.28 USD (+3.87%)
Close
Last updated: August 17, 2026
796M USD
Market cap
Why the stock is moving
As of Aug 17, 2026, KURA closed up 3.87% at $11.28. No new same-company headline was identified in the current news window.
Company overview
Precision Oncology Company
Kura Oncology develops and commercializes small-molecule therapies for genetically defined cancers. Its portfolio focuses on menin inhibition in hematologic malignancies and farnesyl-transferase inhibition in solid tumors.
KOMZIFTI
KOMZIFTI, or ziftomenib, is an FDA-approved oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia. Kura is expanding the drug into earlier treatment settings and genetically defined combination regimens.
Menin Combination Programs
The KOMET clinical program evaluates ziftomenib with venetoclax and azacitidine, intensive chemotherapy, and FLT3 inhibitors. These studies seek to establish ziftomenib as a therapeutic backbone across the AML treatment continuum.
Darlifarnib
Darlifarnib is a farnesyl-transferase inhibitor being developed as a precision combination agent in solid tumors. Current programs combine it with cabozantinib in renal-cell carcinoma and targeted RAS therapies in KRAS-mutated cancers.
Emerging Menin Pipeline
Kura is also advancing next-generation menin inhibitors, including KO-7246 for diabetes and cardiometabolic disease, extending its menin expertise beyond oncology.
Future catalysts
- Updated KOMET-007 data for ziftomenib plus venetoclax and azacitidine in newly diagnosed AML in the second half of 2026.
- Initial KOMET-007 data for ziftomenib with intensive chemotherapy and quizartinib in the second half of 2026.
- Initial KOMET-008 data for ziftomenib plus gilteritinib in relapsed or refractory AML in the second half of 2026.
- Completion of enrollment in the randomized Phase 1b FIT-001 study of darlifarnib plus cabozantinib in the first half of 2027.
- Initiation of a darlifarnib and daraxonrasib platform study in second-line or later pancreatic cancer in the first half of 2027.
- Initial clinical data from the randomized FIT-001 expansion in the second half of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Kura Oncology (KURA)?
Kura Oncology (KURA) most recently closed at 11.28 USD, a +3.87% move versus the previous session.
What is the market cap of Kura Oncology (KURA)?
Kura Oncology currently has a market capitalization of 796M USD on BioPharmSignal.
What does Kura Oncology do?
Precision Oncology Company Kura Oncology develops and commercializes small-molecule therapies for genetically defined cancers. Its portfolio focuses on menin inhibition in hematologic malignancies and farnesyl-transferase inhibition in solid tumors. KOMZIFTI KOMZIFTI, or ziftomenib, is an FDA-approved oral menin inhibitor for adults with relapsed or...
On which exchange is KURA stock listed?
Kura Oncology (KURA) is associated with NASDAQ, United States, Biopharma.
What is KO-7246?
Emerging Menin Pipeline Kura is also advancing next-generation menin inhibitors, including KO-7246 for diabetes and cardiometabolic disease, extending its menin expertise beyond oncology.
Which conditions is Kura Oncology targeting with KO-7246?
Kura Oncology is associated with oncology, cancer therapeutics, metabolic disease based on its company overview and current catalyst commentary.
How does Kura Oncology describe recent progress with KO-7246?
Updated KOMET-007 data for ziftomenib plus venetoclax and azacitidine in newly diagnosed AML in the second half of 2026. Initial KOMET-007 data for ziftomenib with intensive chemotherapy and quizartinib in the second half of 2026. Initial KOMET-008 data for ziftomenib plus gilteritinib in relapsed or refractory AML in the second half of 2026. Completion of...
What is KOMET-007?
Updated KOMET-007 data for ziftomenib plus venetoclax and azacitidine in newly diagnosed AML in the second half of 2026.